Unknown

Dataset Information

0

Homotypic cell membrane-cloaked biomimetic nanocarrier for the accurate photothermal-chemotherapy treatment of recurrent hepatocellular carcinoma.


ABSTRACT: BACKGROUND:Tumor recurrence in patients after surgery severely reduces the survival rate of surgical patients. Targeting and killing recurrent tumor cells and tissues is extremely important for the cancer treatment. RESULTS:Herein, we designed a nano-biomimetic photothermal-controlled drug-loading platform HepM-TSL with good targeting ability and immunocompatibility for the treatment of recurrent hepatocellular carcinoma. HepM-TSL can accurately target the recurrent tumor area with the aid of the cloaked homotypic cell membrane and release the chemotherapy drugs in a controlled manner. In vivo results have confirmed that HepM-TSL loaded with drugs and photosensitizer achieves the synergistic treatment of recurrent hepatocellular carcinoma with good therapeutic effect and slight side effects. CONCLUSION:Accordingly, HepM-TSL provides a sound photothermal-chemotherapy synergistic strategy for the treatment of other recurrent cancers besides of recurrent hepatocellular carcinoma.

SUBMITTER: Sun Y 

PROVIDER: S-EPMC7164213 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Homotypic cell membrane-cloaked biomimetic nanocarrier for the accurate photothermal-chemotherapy treatment of recurrent hepatocellular carcinoma.

Sun Yingxue Y   Zhai Wenhui W   Liu Xiaojun X   Song Xiangyi X   Gao Xiaonan X   Xu Kehua K   Tang Bo B  

Journal of nanobiotechnology 20200416 1


<h4>Background</h4>Tumor recurrence in patients after surgery severely reduces the survival rate of surgical patients. Targeting and killing recurrent tumor cells and tissues is extremely important for the cancer treatment.<h4>Results</h4>Herein, we designed a nano-biomimetic photothermal-controlled drug-loading platform HepM-TSL with good targeting ability and immunocompatibility for the treatment of recurrent hepatocellular carcinoma. HepM-TSL can accurately target the recurrent tumor area wit  ...[more]

Similar Datasets

| S-EPMC6735366 | biostudies-literature
| S-EPMC6781301 | biostudies-literature
| S-EPMC7284223 | biostudies-literature
| S-EPMC6956810 | biostudies-literature
| S-EPMC8725828 | biostudies-literature
| S-EPMC7178525 | biostudies-literature
| S-EPMC3831007 | biostudies-literature
| S-EPMC8601127 | biostudies-literature
| S-EPMC8286575 | biostudies-literature
| S-EPMC7019169 | biostudies-literature